Which antidepressant is associated with the lowest rate of gastrointestinal irritation?

Bupropion and Mirtazapine Cause the Least GI Upset

For minimizing gastrointestinal side effects, bupropion is the best choice among antidepressants, followed by mirtazapine and agomelatine. These agents consistently demonstrate the lowest rates of nausea, vomiting, diarrhea, and other GI adverse effects across multiple high-quality studies.

Evidence-Based Ranking

Lowest GI Side Effects (Best Tolerability)

Bupropion stands out as having minimal GI effects. The 2008 American College of Physicians guideline notes that bupropion has significantly lower rates of sexual adverse events compared to SSRIs, and importantly, it is not associated with the typical GI side effects seen with serotonergic agents 1. This makes physiologic sense given its norepinephrine-dopamine reuptake inhibition mechanism, which doesn't directly affect gut serotonin receptors.

Mirtazapine is the second-best option. The most recent 2025 network meta-analysis specifically identified mirtazapine as "the antidepressant with fewer side effects on the gut, being only associated with increased appetite" 2. A 2025 study confirmed that "trazodone, amitriptyline, agomelatine, and mirtazapine tend to be better tolerated" regarding GI effects 3. While mirtazapine can cause constipation or diarrhea, these rates are substantially lower than SSRIs 4.

Agomelatine also demonstrates favorable GI tolerability, ranking among the best-tolerated options 3.

Moderate to High GI Side Effects (Avoid if GI Tolerability is Priority)

SSRIs cause significant GI upset, particularly:

• Sertraline: Higher rates of diarrhea than most other antidepressants 1
• Escitalopram and sertraline: "Shown to be the least tolerated antidepressants on the gastrointestinal tract, being associated with all the considered SEs with the exception of constipation and increased appetite" 2
• Fluvoxamine: Associated with higher diarrhea rates 3
• Paroxetine: Higher nausea/vomiting rates than other SSRIs 1

SNRIs cause substantial nausea:

• Duloxetine, levomilnacipran, and venlafaxine: Carry the highest risk for nausea and vomiting 3. The 2021 AGA guideline notes duloxetine causes "nausea, headache, fatigue" as common side effects 4.
• Vilazodone: Particularly high rates of both nausea/vomiting and diarrhea 3

Tricyclic antidepressants have mixed profiles:

• Amitriptyline: High rates of constipation, dry mouth, anorexia, and dyspepsia 3
• Clomipramine and reboxetine: Prone to cause constipation 3

Clinical Algorithm for Selection

Step 1: If GI tolerability is the primary concern:

• First choice: Bupropion (virtually no GI effects)
• Second choice: Mirtazapine (minimal GI effects, but watch for increased appetite/weight gain)
• Third choice: Agomelatine (if available)

Step 2: If patient has specific bowel patterns:

• IBS with diarrhea: Consider tricyclic antidepressants (TCAs) like amitriptyline at low doses (10 mg at night), as constipation becomes a therapeutic benefit 5, 6. However, expect dry mouth and sedation.
• IBS with constipation: Avoid TCAs entirely. Use bupropion or consider SSRIs if GI side effects can be tolerated, as they may promote bowel movements 6.

Step 3: Avoid these if GI tolerability matters:

• Never use: Duloxetine, levomilnacipran, vilazodone (highest nausea rates)
• Use cautiously: Sertraline, escitalopram, fluvoxamine (high diarrhea/nausea rates)

Important Caveats

Nausea and vomiting are the most common reasons for antidepressant discontinuation in clinical trials 1. This makes initial drug selection critical for treatment adherence.

The "start low, go slow" principle doesn't eliminate GI side effects for serotonergic agents—it only delays their onset. The 2021 guidelines recommend starting TCAs at 10 mg and titrating by 10 mg weekly 4, but this strategy is less relevant for SSRIs/SNRIs where GI effects are mechanism-based.

Sex differences may exist: One study found fluoxetine had greater gastroprotective effects in male rodents than females 7, suggesting potential sex-based differences in GI tolerability that warrant consideration.

Drug-drug interactions: Bupropion lowers seizure threshold at higher doses, while mirtazapine causes sedation that may be problematic for some patients 1.

The evidence consistently demonstrates that mechanism of action predicts GI tolerability: agents without significant serotonergic effects (bupropion, mirtazapine) cause minimal GI upset, while those with strong serotonergic activity (SSRIs, SNRIs) cause substantial nausea, vomiting, and altered bowel habits 3, 2.